Literature DB >> 8300410

Recognition by HLA-A2-restricted cytotoxic T lymphocytes of endogenously generated and exogenously provided synthetic peptide analogues of the influenza A virus matrix protein.

S Y Sauma1, M C Gammon, M A Bednarek, B Cunningham, W E Biddison, J D Hermes, G Porter, S Tamhankar, J C Hawkins, B L Bush.   

Abstract

Experiments were carried out to determine whether complexes between MHC class I molecules and synthetic peptides are representative of those formed under more physiologically relevant conditions, with peptides derived intracellularly from processed antigens. Lysis of cells sensitized with exogenously provided and endogenously generated peptide analogues of the optimal nonameric peptide 58-66 (GILGFVFTL; derived from the influenza virus matrix protein) was compared. Endogenous loading was accomplished by expressing minigene DNA coding for alanine-substituted analogues of peptide 58-66 in HLA-A2-positive cells. Susceptibility to lysis by HLA-A2-restricted, peptide-specific cytotoxic lymphocytes was compared with lysis of cells sensitized with the same synthetic peptides. Although results were quite comparable, differences were observed. The endogenously presented analogues 58-66L60A, G61A, T65A, and L66A were recognized more efficiently than the corresponding exogenously presented analogues. This difference in recognition was most striking for peptide 58-66G61A. These results indicate the need for caution in using synthetic peptides in defining peptide binding motifs. Additional experiments with endogenously expressed analogues of 58-66 with substitutions other than alanine were carried out to define the interaction between this peptide and HLA-A2. Results are compatible with the interpretation that residues 58, 59, and 60 interact with pockets A, B, and D, respectively, in the HLA-A2 binding groove and that these interactions contribute to peptide binding.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8300410     DOI: 10.1016/0198-8859(93)90508-x

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  7 in total

1.  HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase.

Authors:  Brian M Olson; Thomas P Frye; Laura E Johnson; Lawrence Fong; Keith L Knutson; Mary L Disis; Douglas G McNeel
Journal:  Cancer Immunol Immunother       Date:  2010-02-06       Impact factor: 6.968

2.  CD8+ T cells specific for the androgen receptor are common in patients with prostate cancer and are able to lyse prostate tumor cells.

Authors:  Brian M Olson; Douglas G McNeel
Journal:  Cancer Immunol Immunother       Date:  2011-02-25       Impact factor: 6.968

3.  Vaccines targeting the cancer-testis antigen SSX-2 elicit HLA-A2 epitope-specific cytolytic T cells.

Authors:  Heath A Smith; Douglas G McNeel
Journal:  J Immunother       Date:  2011-10       Impact factor: 4.456

4.  Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients.

Authors:  K L Knutson; K Schiffman; M L Disis
Journal:  J Clin Invest       Date:  2001-02       Impact factor: 14.808

5.  Attenuated Listeria monocytogenes vaccine vectors expressing influenza A nucleoprotein: preclinical evaluation and oral inoculation of volunteers.

Authors:  Paul V Johnson; Barbra M Blair; Skye Zeller; Camille N Kotton; Elizabeth L Hohmann
Journal:  Microbiol Immunol       Date:  2011-05       Impact factor: 1.955

6.  Pilot study of an HLA-A2 peptide vaccine using flt3 ligand as a systemic vaccine adjuvant.

Authors:  Douglas G McNeel; Keith L Knutson; Kathy Schiffman; Donna R Davis; Dania Caron; Mary L Disis
Journal:  J Clin Immunol       Date:  2003-01       Impact factor: 8.317

7.  The androgen receptor: a biologically relevant vaccine target for the treatment of prostate cancer.

Authors:  Brian M Olson; Laura E Johnson; Douglas G McNeel
Journal:  Cancer Immunol Immunother       Date:  2012-10-30       Impact factor: 6.968

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.